$190 Million is the total value of Birchview Capital, LP's 38 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 15.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CELG | Buy | CELGENE CORP | $96,854,000 | +6.4% | 840,163 | +3.2% | 50.88% | -3.7% |
| AXDX | Buy | ACCELERATE DIAGNOSTICS INC | $46,520,000 | +17.4% | 2,067,560 | +0.1% | 24.44% | +6.2% |
| MBLX | METABOLIX INC | $7,629,000 | +50.6% | 12,705,000 | 0.0% | 4.01% | +36.3% | |
| VRML | VERMILLION INC | $4,687,000 | -11.1% | 2,717,514 | 0.0% | 2.46% | -19.5% | |
| EQT | EQT CORP | $3,423,000 | +9.5% | 41,300 | 0.0% | 1.80% | -0.9% | |
| MDVN | MEDIVATION INC | $2,798,000 | +29.5% | 21,680 | 0.0% | 1.47% | +17.2% | |
| HNSN | HANSEN MEDICAL | $2,541,000 | +56.6% | 2,920,928 | 0.0% | 1.34% | +41.7% | |
| BIOL | BIOLASE INC | $2,396,000 | -23.2% | 1,185,903 | 0.0% | 1.26% | -30.5% | |
| SWN | SOUTHWESTERN ENERGY CO | $2,237,000 | -15.0% | 96,483 | 0.0% | 1.18% | -23.2% | |
| GILD | GILEAD SCIENCES INC | $1,832,000 | +4.1% | 18,670 | 0.0% | 0.96% | -5.9% | |
| CLR | CONTINENTAL RESOURCES INC | $1,427,000 | +13.9% | 32,674 | 0.0% | 0.75% | +3.2% | |
| MASI | MASIMO CORP | $1,207,000 | +25.2% | 36,600 | 0.0% | 0.63% | +13.2% | |
| AEGR | New | AEGERION PHARMACEUTICALS INC | $1,204,000 | – | 46,000 | +100.0% | 0.63% | – |
| OMED | Buy | ONCOMED PHARMACEUTICALS INC | $1,152,000 | +135.6% | 44,689 | +98.7% | 0.60% | +113.0% |
| ARAY | Sell | ACCURAY INC | $1,119,000 | +3.4% | 120,300 | -16.1% | 0.59% | -6.4% |
| QDEL | QUIDEL CORP | $1,052,000 | -6.7% | 38,975 | 0.0% | 0.55% | -15.4% | |
| TTHI | TRANSITION THERAPEUTICS INC | $1,030,000 | -0.1% | 150,746 | 0.0% | 0.54% | -9.7% | |
| PTCT | Sell | PTC THERAPEUTICS INC | $1,028,000 | -0.2% | 16,900 | -15.1% | 0.54% | -9.7% |
| ASPX | Sell | AUSPEX PHARMACEUTICALS INC | $902,000 | -32.6% | 9,000 | -64.7% | 0.47% | -39.0% |
| MRK | MERCK & CO INC | $862,000 | +1.2% | 15,000 | 0.0% | 0.45% | -8.5% | |
| TRNX | Sell | TORNIER N V | $787,000 | -37.0% | 30,000 | -38.8% | 0.41% | -43.1% |
| ECA | ENCANA CORP | $777,000 | -19.6% | 69,700 | 0.0% | 0.41% | -27.3% | |
| XNCR | New | XENCOR INC | $766,000 | – | 50,000 | +100.0% | 0.40% | – |
| CELGZ | CELGENE CORPright 12/31/2030 | $634,000 | -5.7% | 213,432 | 0.0% | 0.33% | -14.6% | |
| COG | CABOT OIL & GAS CORP | $620,000 | -0.3% | 21,000 | 0.0% | 0.33% | -9.7% | |
| BIIB | BIOGEN IDEC INC | $591,000 | +24.4% | 1,400 | 0.0% | 0.31% | +12.3% | |
| PBYI | PUMA BIOTECHNOLOGY INC | $508,000 | +24.8% | 2,150 | 0.0% | 0.27% | +13.1% | |
| MACK | MERRIMACK PHARMACEUTICALS IN | $503,000 | +5.2% | 42,300 | 0.0% | 0.26% | -5.0% | |
| PXD | PIONEER NAT RES CO | $491,000 | +9.8% | 3,000 | 0.0% | 0.26% | -0.8% | |
| ROKA | Buy | ROKA BIOSCIENCE INC | $487,000 | +28.5% | 152,307 | +77.3% | 0.26% | +16.4% |
| CERS | New | CERUS CORP | $346,000 | – | 83,000 | +100.0% | 0.18% | – |
| RPTP | New | RAPTOR PHARMACEUTICAL CORP | $326,000 | – | 30,000 | +100.0% | 0.17% | – |
| AGIO | AGIOS PHARMACEUTICALS INC | $321,000 | -15.7% | 3,400 | 0.0% | 0.17% | -23.5% | |
| QTNT | Sell | QUOTIENT LTD | $309,000 | -56.8% | 18,200 | -54.2% | 0.16% | -61.0% |
| PQ | PETROQUEST ENERGY INC | $281,000 | -38.4% | 122,050 | 0.0% | 0.15% | -44.2% | |
| NXTM | NXSTAGE MEDICAL INC | $254,000 | -3.8% | 14,700 | 0.0% | 0.13% | -13.1% | |
| CHRS | New | COHERUS BIOSCIENCES INC | $229,000 | – | 7,500 | +100.0% | 0.12% | – |
| NSPR | Buy | INSPIREMD INC | $214,000 | +62.1% | 670,000 | +294.1% | 0.11% | +45.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2015-05-07
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACCELERATE DIAGNOSTICS INC | 36 | Q3 2023 | 34.6% |
| QUIDELORTHO CORP | 36 | Q3 2023 | 8.6% |
| MASIMO CORP | 36 | Q3 2023 | 2.2% |
| PIONEER NATURAL RESOURCES CO (PXD) | 36 | Q3 2023 | 0.7% |
| XENCOR INC | 35 | Q3 2023 | 0.4% |
| NEUROCRINE BIOSCIENCES INC | 33 | Q3 2023 | 7.4% |
| CORCEPT THERAPEUTICS INC | 32 | Q3 2023 | 1.2% |
| BIOGEN INC | 31 | Q2 2022 | 3.1% |
| CONTRAFECT CORP | 30 | Q3 2022 | 1.6% |
| YIELD10 BIOSCIENCE INC | 26 | Q3 2023 | 0.6% |
View Birchview Capital, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SOLENO THERAPEUTICS INC | March 19, 2019 | 742,635 | 2.3% |
| YIELD10 BIOSCIENCE, INC. | December 29, 2017 | 186,079 | 2.2% |
| HANSEN MEDICAL INC | February 16, 2016 | ? | ? |
| METABOLIX, INC. | June 23, 2015 | 749,696 | 2.8% |
View Birchview Capital, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3/A | 2024-02-20 |
| 4/A | 2024-02-20 |
| SC 13G/A | 2024-02-20 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-04-07 |
| 4 | 2023-03-27 |
| 3 | 2023-02-13 |
View Birchview Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.